The availability of remdesevir is limited. The trial is leronlimab vs SOC at each trial site. Patients was or may not receive remdesivir. Cytodyn also recognized, IMO, that it is better the demonstrated leronlimab efficacy without remdesivir in the conversation.

SOC varies over time and among institutions. HCQ was SOC three months ago. Would we have wanted to restart the trials after HCQ administration was curtailed?